Literature DB >> 20692200

Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.

Zhiwei Wang1, Yiwei Li, Aamir Ahmad, Asfar S Azmi, Dejuan Kong, Sanjeev Banerjee, Fazlul H Sarkar.   

Abstract

Although chemotherapy is an important therapeutic strategy for cancer treatment, it fails to eliminate all tumor cells due to intrinsic or acquired drug resistance, which is the most common cause of tumor recurrence. Emerging evidence suggests an intricate role of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT)-type cells in anticancer drug resistance. Recent studies also demonstrated that microRNAs (miRNAs) play critical roles in the regulation of drug resistance. Here we will discuss current knowledge regarding CSCs, EMT and the role of regulation by miRNAs in the context of drug resistance, tumor recurrence and metastasis. A better understanding of the molecular intricacies of drug-resistant cells will help to design novel therapeutic strategies by selective targeting of CSCs and EMT-phenotypic cells through alterations in the expression of specific miRNAs towards eradicating tumor recurrence and metastasis. A particular promising lead is the potential synergistic combination of natural compounds that affect critical miRNAs, such as curcumin or epigallocatechin-3-gallate (EGCG) with chemotherapeutic agents.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20692200      PMCID: PMC2956795          DOI: 10.1016/j.drup.2010.07.001

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  154 in total

Review 1.  Trastuzumab resistance: role for Notch signaling.

Authors:  Kinnari Mehta; Clodia Osipo
Journal:  ScientificWorldJournal       Date:  2009-12-16

Review 2.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

Review 3.  The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.

Authors:  Yong Lin; Lang Bai; Wenjie Chen; Shanling Xu
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

4.  Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.

Authors:  Mohd W Nasser; Jharna Datta; Gerard Nuovo; Huban Kutay; Tasneem Motiwala; Sarmila Majumder; Bo Wang; Saul Suster; Samson T Jacob; Kalpana Ghoshal
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

Review 5.  PDGF-D signaling: a novel target in cancer therapy.

Authors:  Zhiwei Wang; Dejuan Kong; Yiwei Li; Fazlul H Sarkar
Journal:  Curr Drug Targets       Date:  2009-01       Impact factor: 3.465

Review 6.  Exploitation of the Notch signaling pathway as a novel target for cancer therapy.

Authors:  Zhiwei Wang; Yiwei Li; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  Anticancer Res       Date:  2008 Nov-Dec       Impact factor: 2.480

7.  microRNA-205 regulates HER3 in human breast cancer.

Authors:  Marilena V Iorio; Patrizia Casalini; Claudia Piovan; Gianpiero Di Leva; Andrea Merlo; Tiziana Triulzi; Sylvie Ménard; Carlo M Croce; Elda Tagliabue
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

8.  Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.

Authors:  Jin Kyung Rho; Yun Jung Choi; Jin Kyung Lee; Baek-Yeol Ryoo; Im Il Na; Sung Hyun Yang; Cheol Hyeon Kim; Jae Cheol Lee
Journal:  Lung Cancer       Date:  2008-07-02       Impact factor: 5.705

Review 9.  The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies.

Authors:  Brett G Hollier; Kurt Evans; Sendurai A Mani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-02-26       Impact factor: 2.673

Review 10.  Emerging role of Notch in stem cells and cancer.

Authors:  Zhiwei Wang; Yiwei Li; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2008-11-20       Impact factor: 8.679

View more
  138 in total

Review 1.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

2.  Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals.

Authors:  Alejandro Vazquez-Martin; Salvador Fernández-Arroyo; Sílvia Cufí; Cristina Oliveras-Ferraros; Jesús Lozano-Sánchez; Luciano Vellón; Vicente Micol; Jorge Joven; Antonio Segura-Carretero; Javier A Menendez
Journal:  Rejuvenation Res       Date:  2012-01-09       Impact factor: 4.663

Review 3.  The two faces of FBW7 in cancer drug resistance.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Daming Gao; Hiroyuki Inuzuka; Lixin Wan; Alan W Lau; Pengda Liu; Wenyi Wei
Journal:  Bioessays       Date:  2011-08-30       Impact factor: 4.345

4.  Systems-level Analysis Reveals Multiple Modulators of Epithelial-mesenchymal Transition and Identifies DNAJB4 and CD81 as Novel Metastasis Inducers in Breast Cancer.

Authors:  Zeynep Cansu Uretmen Kagiali; Erdem Sanal; Özge Karayel; Ayse Nur Polat; Özge Saatci; Pelin Gülizar Ersan; Kathrin Trappe; Bernhard Y Renard; Tamer T Önder; Nurcan Tuncbag; Özgür Şahin; Nurhan Ozlu
Journal:  Mol Cell Proteomics       Date:  2019-06-20       Impact factor: 5.911

Review 5.  Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Yiwei Li; Aamir Ahmad; Shadan Ali; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Curr Stem Cell Res Ther       Date:  2014-01       Impact factor: 3.828

6.  miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.

Authors:  Shujing Liu; Michael T Tetzlaff; Tao Wang; Ruifeng Yang; Lin Xie; Gao Zhang; Clemens Krepler; Min Xiao; Marilda Beqiri; Wei Xu; Giorgos Karakousis; Lynn Schuchter; Ravi K Amaravadi; Weiting Xu; Zhi Wei; Meenhard Herlyn; Yuan Yao; Litao Zhang; Yingjie Wang; Lin Zhang; Xiaowei Xu
Journal:  Pigment Cell Melanoma Res       Date:  2015-05-16       Impact factor: 4.693

7.  Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.

Authors:  Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Antonio Segura-Carretero; Jorge Joven; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Cell Cycle       Date:  2013-09-17       Impact factor: 4.534

8.  Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells.

Authors:  Donghai Jiang; Meihua Sui; Wangyan Zhong; Yuan Huang; Weimin Fan
Journal:  Cancer Lett       Date:  2013-03-07       Impact factor: 8.679

9.  Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1.

Authors:  Kewei Zhu; Wanchun Wang
Journal:  Tumour Biol       Date:  2015-10-24

10.  microRNA-based cancer cell reprogramming technology.

Authors:  Shimpei Nishikawa; Hideshi Ishii; Naotsugu Haraguchi; Yoshihiro Kano; Takahito Fukusumi; Katsuya Ohta; Miyuki Ozaki; Dyah Laksmi Dewi; Daisuke Sakai; Taroh Satoh; Hiroaki Nagano; Yuichiro Doki; Masaki Mori
Journal:  Exp Ther Med       Date:  2012-04-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.